Key facts
- Notable investors include Nanjing Jiangbei Yihua Private Equity Fund Management, Beijing Shangshi Investment Management, Chang'an Capital, Nanjing Jiangbei New Area Science and Technology Investment Group.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Suzhou Yuanxing Technology
- ·The full record, as it builds
Funding rounds
No funding rounds for Suzhou Yuanxing Technology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Suzhou Yuanxing Technology
Developer of a research tool platform intended to assist innovative drug discovery, clinical applications, and translational medicine. The company offers universal multi-omics tool platforms that provide innovative research processes for drug discovery, translational medicine, and clinical applications with an unmatched combination of superior cost and performance, enabling users with the ability to effectively detect markers in tissue section samples in drug discovery, clinical applications, and translational medicine.
- Sector
- Healthcare
- HQ
- Suzhou, China
- Founded
- 2022
- Ownership
- Privately Held (backing)
Suzhou Yuanxing Technology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Suzhou Yuanxing Technology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Suzhou Yuanxing Technology in its N-PORT filings yet. We sweep new filings monthly.